Seminars in arthritis and rheumatism最新文献

{"title":"Optimal modality and dose of exercise for relieving pain in patients with knee or hip osteoarthritis: Bayesian pairwise, network, and dose-response meta-analyses","authors":"Zhide Liang ,&nbsp;Chuanzhi Wang ,&nbsp;Meng Zhang ,&nbsp;Yingdanni Yu ,&nbsp;Fengwei Hao ,&nbsp;Shudong Tian","doi":"10.1016/j.semarthrit.2025.152855","DOIUrl":"10.1016/j.semarthrit.2025.152855","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the effects of different exercise modalities and doses on pain in patients with knee or hip osteoarthritis (OA).</div></div><div><h3>Methods</h3><div>A systematic search of six electronic databases was conducted, from database inception to December 2024, to identify randomized controlled trials (RCTs) on exercise interventions in patients with knee or hip OA. Bayesian pairwise, network, and dose–response meta-analyses were conducted using a random-effects model to analyze the impact of exercise on pain in knee or hip OA. Two reviewers independently assessed the quality of the literature.</div></div><div><h3>Results</h3><div>A total of 92 RCTs involving 6079 participants were analyzed. Aerobic training was found to have the highest likelihood of ranking first in effectiveness (Surface Under the Cumulative Ranking curve [SUCRA]: 84.7%; Standardized Mean Difference [SMD]: -1.00; 95% CrI: -1.50, -0.62), followed by strength combined with flexibility training (SUCRA: 73.0%; SMD: -0.93; 95% CrI: -1.40, -0.50), yoga (SUCRA: 63.7%; SMD: -0.86; 95% CrI: -1.50, -0.24), and strength training (SUCRA: 55.9%; SMD: -0.78; 95% CrI: -1.00, -0.55); flexibility training (SUCRA: 39.8%; SMD: -0.65; 95% CrI: -1.10, -0.22) ranked the lowest. However, there were no significant differences in effectiveness among the exercise types. When pooling data from all exercise modalities, a 'U-shaped' dose-response relationship was observed between the overall exercise dose and pain.</div></div><div><h3>Conclusions</h3><div>Exercise effectively reduces pain in patients with knee or hip OA. Although no exercise type was found to be statistically superior to another, based on probabilistic ranking, aerobic training, strength combined with flexibility training, yoga, and strength training had the highest likelihood of being the most effective interventions. The analysis identified that the optimal dose for maximizing pain relief was 620 metabolic equivalent of task (METs)-min/week (SMD: -0.93; 95% CrI: -1.24 to -0.58) (equivalent to, for example, approximately 120 min of moderate-intensity water aerobics per week), while the minimum dose to achieve a clinically important difference was 180 METs-min/week. However, given the methodological limitations of the analysis and the overall low to moderate certainty of the evidence, these findings should be interpreted with caution.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152855"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease","authors":"Justine P. Enns ,&nbsp;Jiaqi Wang ,&nbsp;Bohang Jiang ,&nbsp;Shruthi Srivatsan ,&nbsp;Emily N. Kowalski ,&nbsp;Xiaosong Wang ,&nbsp;Zachary K. Williams ,&nbsp;Grace Qian ,&nbsp;Jennifer Hanberg ,&nbsp;Colebrooke Johnson ,&nbsp;Madison Negron ,&nbsp;Katarina J. Bade ,&nbsp;Alene Saavedra ,&nbsp;Kevin T. Mueller ,&nbsp;Kathleen M.M. Vanni ,&nbsp;Camille N. Kotton ,&nbsp;Jeffrey A. Sparks ,&nbsp;Zachary S. Wallace ,&nbsp;Naomi J. Patel","doi":"10.1016/j.semarthrit.2025.152846","DOIUrl":"10.1016/j.semarthrit.2025.152846","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) is a common respiratory viral illness which can cause severe outcomes in older and immunosuppressed populations. There is little data regarding RSV outcomes among people with systemic autoimmune rheumatic diseases (SARDs).</div></div><div><h3>Methods</h3><div>This retrospective cohort study examined risk factors for hospitalization in individuals with SARDs and documented RSV infection between 2015 and 2023 at Mass General Brigham (Boston, MA). Clinical data were collected from electronic health records. Multivariable adjusted logistic regression was used to identify factors associated with hospitalization for RSV infection.</div></div><div><h3>Results</h3><div>Of 188 individuals with SARDs and RSV (mean age 68.5 years, 75.5% female), 96 (51.0%) were hospitalized. Higher Charlson Comorbidity Index (aOR 1.16 per point, 95% CI: 1.04-1.31), Claims-Based Frailty Index (aOR 4.80 vs. robust/pre-frail, 95% CI: 2.32-9.94), and concurrent infection (aOR 2.52 vs. RSV alone, 95% CI: 1.07-5.92) were associated with increased odds of hospitalization. CD20 inhibitor treatment (aOR 3.84 vs. csDMARD, 95% CI: 0.99-15.20) and older age (OR 1.03 per year, 95% CI: 1.01-1.05) were associated with numerically increased odds of RSV hospitalization. Among hospitalized individuals, 56% required oxygen. There were 12 deaths within 90 days (12.5% of those hospitalized; 6% of all with RSV).</div></div><div><h3>Conclusions</h3><div>This study highlights the increased risk of severe outcomes of RSV infection in individuals with SARDs. Factors associated with RSV hospitalization included frailty, higher comorbidity burden, and concurrent infection at the time of RSV. These findings should inform clinical decisions regarding RSV vaccination and prevention strategies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152846"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study design and protocol of a randomized, pragmatic, comparative effectiveness trial evaluating a sequenced strategy for improving outcomes in people with knee osteoarthritis pain (SKOAP): Conservative treatment evaluation","authors":"Heavon M. Allen ,&nbsp;Melinda M. Holena ,&nbsp;Lauren E. Allen ,&nbsp;SiNing Zhao ,&nbsp;Renan C. Castillo ,&nbsp;Steven P. Cohen ,&nbsp;Robert W. Hurley ,&nbsp;Daniel O. Scharfstein ,&nbsp;Jennifer A. Haythornthwaite ,&nbsp;Srinivasa N. Raja ,&nbsp;Stephen T. Wegener ,&nbsp;Christine M. Rini ,&nbsp;Francis J. Keefe ,&nbsp;Jordan Bridges ,&nbsp;Ron Reeder ,&nbsp;Richard E. Thompson ,&nbsp;Dan Hanley ,&nbsp;Claudia M. Campbell ,&nbsp;the SKOAP Consortium","doi":"10.1016/j.semarthrit.2025.152834","DOIUrl":"10.1016/j.semarthrit.2025.152834","url":null,"abstract":"<div><h3>Background</h3><div>Treatment guidelines for knee osteoarthritis (KOA) vary across organizations, partly due to the lack of high-quality evidence. Experts disagree on the role of psychological management, pharmacologic treatments including opioids, and interventional therapies.</div></div><div><h3>Methods/Design</h3><div>The Sequenced strategy for Knee OsteoArthritis Pain (SKOAP) trial is a multi-site, randomized, pragmatic clinical trial that uses a two-phase sequential design to evaluate the effectiveness of several interventions in individuals reporting KOA pain. Described here is the protocol for Phase 1 of the trial sequence which focuses on conservative treatments. All participants receive Best Practices (BP), a guideline-based approach to care that includes physical therapies, alternative treatments, and over-the-counter medications. Participants are then randomized to one of three groups: (1) BP alone, (2) BP plus duloxetine (30–120 mg/day), or (3) BP plus duloxetine and painTRAINER, a web-based, Cognitive Behavioral Therapy (CBT)-informed pain coping skills training. Phase 1 aims to determine whether the combination of duloxetine and BP improves pain compared to BP alone, and whether the combination of painTRAINER, duloxetine and BP provides additional benefit compared to duloxetine combined with BP. The analysis will include a modified Intention to Treat (mITT) approach and two Per-Protocol (PP) analyses; Receipt of Prescription (PP-ROP) and Minimum Effective Dose (PP-MinED). A third aim of Phase 1 is to identify clinical characteristics, patient-level factors, and psychosocial phenotypes that predict short- and long-term outcomes.</div></div><div><h3>Discussion</h3><div>Findings from Phase 1 of the SKOAP trial will provide evidence on the effectiveness of non-opioid pharmacologic and psychological interventions for the treatment of painful KOA beyond established best practices. It may also help refine personalized treatment strategies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152834"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty carries an increased risk of death in rheumatoid arthritis","authors":"Sayuli A. Bhide ,&nbsp;Punyasha Roul ,&nbsp;Bryant R. England ,&nbsp;Hannah F. Brubeck ,&nbsp;Grant W Cannon ,&nbsp;Namrata Singh ,&nbsp;Courtney Loecker ,&nbsp;Gary Kunkel ,&nbsp;Ted R. Mikuls ,&nbsp;Dolores M. Shoback ,&nbsp;Kaleb Michaud ,&nbsp;Patricia P. Katz ,&nbsp;Jose M. Garcia ,&nbsp;Ariela R. Orkaby ,&nbsp;Joshua F. Baker ,&nbsp;Katherine D. Wysham","doi":"10.1016/j.semarthrit.2025.152872","DOIUrl":"10.1016/j.semarthrit.2025.152872","url":null,"abstract":"<div><h3>Background</h3><div>Frailty is prevalent among people with rheumatoid arthritis (RA) and is a risk factor for adverse outcomes, however the association between frailty and mortality in RA is not well understood.</div></div><div><h3>Methods</h3><div>Participants from the Veterans Association Rheumatoid Arthritis (VARA) Registry enrolled from 1/2003 to 12/2020 were included. Frailty was measured using the VA Frailty Index (VA-FI) which categorized participants as robust, pre-frail, mildly frail, and moderate/severely frail. Multivariable Cox proportional hazard modeling evaluated the relationship between baseline frailty and mortality, adjusted for demographics, disease activity, smoking, and disease treatments.</div></div><div><h3>Findings</h3><div>2792 Veterans were included with mean age of 64.3 years. 2457 (88 %) were male and 459 (17 %) were Black. Of these, 883 (32 %) were robust, 1112 (40 %) prefrail, 520 (19 %) mildly frail, and 277 (10 %) moderately to severely frail. In total, 1283 (46 %) of participants died during the 20 years of observation. The risk of mortality increased with increasing levels of frailty – prefrail aHR 1.46 [95 % CI 1.25 – 1.69], mild frailty aHR 1.97 [95 % CI 1.66 – 2.33], moderate/severe frailty aHR 2.93 [95 % CI 2.39 – 3.59]. The VA-FI frailty domains with the highest association with mortality were morbidities and functional impairments.</div></div><div><h3>Interpretations</h3><div>There is a stepwise increase in mortality risk and decrease in survival time, associated with higher degrees of frailty in RA. Morbidities and functional impairments are associated with the greatest risk increase of mortality. The VA-FI may serve as an important prognostic tool in the RA population.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152872"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to “pathological contributors to organ damage and mortality in systemic sclerosis: a nationwide matched case-control study”","authors":"Dr. Parth Aphale ,&nbsp;Shashank Dokania ,&nbsp;Himanshu Shekhar","doi":"10.1016/j.semarthrit.2025.152839","DOIUrl":"10.1016/j.semarthrit.2025.152839","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152839"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autonomic dysfunction symptoms in Sjögren’s Disease: A missed dimension linked to disease burden and work disability","authors":"Achten Helena ,&nbsp;Deroo Liselotte ,&nbsp;Vanhoof Sophie ,&nbsp;De Boeck Kristel ,&nbsp;Deprez Joke ,&nbsp;Dumas Emilie ,&nbsp;Genbrugge Eva ,&nbsp;Bauters Wouter ,&nbsp;Roels Dimitri ,&nbsp;Dochy Frederick ,&nbsp;Creytens David ,&nbsp;Elewaut Dirk ,&nbsp;Peene Isabelle","doi":"10.1016/j.semarthrit.2025.152832","DOIUrl":"10.1016/j.semarthrit.2025.152832","url":null,"abstract":"<div><h3>Background</h3><div>Autonomic dysfunction (AD) has been reported in Sjögren’s Disease (SjD), but its relationship with established objective and patient-reported outcome measures (PROMs) is unclear.</div></div><div><h3>Objectives</h3><div>The primary aim was to assess AD symptoms in a large SjD cohort and to examine their association with established SjD outcome measures. Secondary, the relationship between AD symptoms and symptom-based endotypes, work disability, and vaginal dryness was evaluated.</div></div><div><h3>Methods</h3><div>The Composite Autonomic Symptom Score 31 (COMPASS-31) was completed by 266 SjD patients from the Belgian Sjögren’s Syndrome Transition Trial. Objective measures included glandular involvement (ultrasound, focus score, sicca tests) and systemic disease activity (European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index). PROMs included EULAR patient reported index, Hospital Anxiety and Depression scale, modified fatigue Impact scale, vaginal dryness and profession. The Newcastle Sjögren’s Stratification Tool stratified patients into 'Low Symptom Burden', 'Dryness Dominant with Fatigue', 'Pain Dominant with Fatigue (PDF)' and 'High Symptom Burden (HSB)'.</div></div><div><h3>Results</h3><div>COMPASS-31 did not correlate with objective measures, but showed significant associations with anxiety (ρ = 0.41), depression (ρ = 0.44), pain (ρ = 0.35), dryness (ρ = 0.29) and fatigue (ρ = 0.37), (<em>p</em> &lt; 0.001). Integrating these PROMS into symptom-based endotypes, COMPASS-31 was highest in HSB and PDF (<em>p</em> &lt; 0.001). COMPASS-31 independently predicted work disability (OR 2.10, 95 % CI 1.29–3.44, <em>p</em> &lt; 0.01) and was higher in premenopausal women with vaginal dryness (<em>p</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>AD symptoms are not captured by established outcome measures but meaningfully contribute to disease burden and work disability. COMPASS-31 may serve as a valuable complementary PROM. Future studies should objectify AD and clarify its pathophysiology.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152832"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Considerations for integrating SGLT2 inhibitors into systemic lupus erythematosus management: Opportunities and challenges” by Chen et al","authors":"Iftach Sagy ,&nbsp;Itamar Ben Shitrit ,&nbsp;Ran Abuhasira ,&nbsp;Ran Ben David ,&nbsp;Yosef S Haviv ,&nbsp;Oshrat Tayer-Shifman ,&nbsp;Mahmoud Abu-Shakra ,&nbsp;Elad Brav ,&nbsp;Nitzan Burrack ,&nbsp;Lior Zeller","doi":"10.1016/j.semarthrit.2025.152868","DOIUrl":"10.1016/j.semarthrit.2025.152868","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152868"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145525277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatic manifestations of alkaptonuria: clinical, genetic and capillaroscopic characterisation of a referral centre cohort reveals new capillaroscopic marker of the disease","authors":"Roberto Pereira da Costa ,&nbsp;Filipa Costa ,&nbsp;João Eurico Fonseca ,&nbsp;Nikita Khmelinskii ,&nbsp;Anabela Oliveira ,&nbsp;Eduardo Dourado","doi":"10.1016/j.semarthrit.2025.152856","DOIUrl":"10.1016/j.semarthrit.2025.152856","url":null,"abstract":"<div><h3>Objectives</h3><div>Alkaptonuria is a rare genetic disorder caused by the build-up of homogentisic acid, leading to its deposition in connective tissue. Previous studies have documented histopathological evidence of extracellular matrix and vessel wall deposits and neoangiogenesis in patients with alkaptonuria, as well as the possible role of dermoscopy in characterising macroscopically visible skin deposits. This proof-of-concept study aimed to describe the capillaroscopic changes in patients with alkaptonuria.</div></div><div><h3>Methods</h3><div>In this cross-sectional single-centre study, alkaptonuria patients were evaluated phenotypically, genetically, and with capillaroscopy. Capillaroscopic findings were compared to three control groups: healthy controls, patients with primary Raynaud’s phenomenon and patients with systemic sclerosis.</div></div><div><h3>Results</h3><div>Ten alkaptonuria patients were included (60 % female, mean age 54.4 ± 12.2 years). All patients had skin and/or sclerae pigmentation and the majority (90 %) had musculoskeletal manifestations. One patient had a normal capillaroscopy. Blue-blackish deposits suggestive of homogentisic acid accumulation were observed in six patients, the majority of which were not visible to the naked eye. None of the patients from the three control groups had this capillaroscopic finding. Nine patients with alkaptonuria presented atypical, non-specific capillaroscopic changes. Notably, we observed a significantly higher prevalence of abnormally shaped capillaries compared both to healthy controls (70.0 % vs 20.0 %, p = 0.034) and to patients with primary Raynaud’s phenomenon (70.0 % vs 20.0 %, p = 0.034), and of dilated capillaries compared to patients with primary Raynaud’s phenomenon (50.0 % vs 13.3 %, p = 0.045).</div></div><div><h3>Conclusions</h3><div>This study is the first to document capillaroscopic changes in alkaptonuria patients, supporting the hypothesis of microcirculation damage in this disease and raising the question of a possible role of capillaroscopy as a diagnostic, prognostic, and disease monitoring tool in this condition.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152856"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies)","authors":"Fadi Kharouf ,&nbsp;Pankti Mehta ,&nbsp;Virginia Carrizo Abarza ,&nbsp;Dafna D Gladman ,&nbsp;Laura P Whittall Garcia ,&nbsp;Zahi Touma","doi":"10.1016/j.semarthrit.2025.152836","DOIUrl":"10.1016/j.semarthrit.2025.152836","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152836"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying domains for CNO and SAPHO: A scoping review to create domains from existing outcomes by the OMERACT CNO and SAPHO working group","authors":"Melissa Oliver ,&nbsp;Farzana Nuruzzaman ,&nbsp;Aleksander Lenert ,&nbsp;Arundathi Jayatilleke ,&nbsp;Alexander Theos ,&nbsp;Natalia Palmou-Fontana ,&nbsp;Alissa Skinner ,&nbsp;Marinka Twilt ,&nbsp;Eveline Y. Wu ,&nbsp;Cassyanne Aguiar ,&nbsp;Samir Shah ,&nbsp;Micol Romano ,&nbsp;Suzanne Li ,&nbsp;Sivia Lapidus ,&nbsp;Jenna King ,&nbsp;Sierra Gerber ,&nbsp;Bethany Welc ,&nbsp;Lindsey Bergstrom ,&nbsp;Emily Fox ,&nbsp;Matthew Hollander ,&nbsp;Yongdong Zhao","doi":"10.1016/j.semarthrit.2025.152862","DOIUrl":"10.1016/j.semarthrit.2025.152862","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic nonbacterial osteomyelitis (CNO) and synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome are autoinflammatory bone diseases of unknown etiology that present with bone pain and varying degrees of extraosseous manifestations such as skin, intestinal and joint involvement. Currently, there are no validated outcome measurement sets that represent the input from all collaborating groups.</div></div><div><h3>Methods</h3><div>The OMERACT CNO &amp; SAPHO working group performed a scoping review to identify domains previously used in CNO and SAPHO clinical studies. The list of potential domains was narrowed through a process of binning and winnowing.</div></div><div><h3>Results</h3><div>A scoping review included 260 observational studies published from 1978 -2020 and 220 domains were initially identified. Domains were reduced to 25 through a binning and winnowing process. Domains cover each of the OMERACT core with most domains mapped to life impact and pathophysiological manifestations.</div></div><div><h3>Conclusion</h3><div>We identified 25 potential domains covering health concepts of function, disease manifestations, pain, and impact on mental health and societal participation to be included in the final core domain set. The next step will be to reach a consensus on the final CNO &amp; SAPHO core domain set and begin instrument selection.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152862"},"PeriodicalIF":4.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}